Scholarlink

Purpose <p>The intricateness of tumor immune microenvironment types (TIMTs) complicates identifying responders to immune checkpoint inhibitors (ICIs). Our purpose was to explore the metabolic characteristics of TIMTs in breast cancer using <sup>18</sup>F-fluorodeoxyglucose (FDG) PET/CT and to establish radiomics-based predictive models for TIMTs.</p> Methods <p>Consecutive 207 breast cancer patients (211 primary lesions), who underwent <sup>18</sup>F-FDG PET/CT examination from Sep 2022 to Aug 2024 in our hospital, were retrospectively reviewed. The programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) were evaluated for TIMTs: TMIT-I (PD-L1-, TILs-), TMIT-II (PD-L1+, TILs+), TMIT-III (PD-L1-, TILs+), and TMIT-IV (PD-L1+, TILs-). The relationship between metabolic parameters (such as maximum standardized uptake value (SUVmax) and tumor-to-liver SUV ratio (TLR)) and TIMTs was analyzed. Then composite predictive models based on radiomics were further developed.</p> Results <p>TIMT-II represented the highest proportion in HER2+ (14/22, 64%) and triple-negative (17/27, 63%) breast cancer. Most metabolic parameters (such as SUVmax and TLR) exhibited significant differences in TIMT-II vs. -I or TIMT-II vs. -III (<i>P</i> &lt; 0.05). TLR (<i>P</i> = 0.03; OR: 1.1) and Nottingham grade (<i>P</i> = 0.006; OR: 3.1) were independent impact factors of TIMT-II. We further developed a composite model that integrated radiomics, metabolic parameter, and clinicopathological data, which demonstrated promising predictive efficacy for TIMT-II (AUC <sub>testing set</sub> = 0.86).</p> Conclusion <p>Metabolic differences existed among different TIMTs, with TIMT-II exhibiting markedly elevated metabolic characteristics. The composite model based on radiomics demonstrated high predictive efficacy for TIMT-II and has the potential to screen ICIs responders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT

  • 期刊论文

  • 发表日期：

    2025年5月6日

查看全文
  • Yuan Gao,
  • Zijian Fu,
  • Xiaojuan Zhu,
  • Hongfeng Li,
  • Lei Yin,
  • Caixia Wu,
  • Jinzhi Chen,
  • Yulong Chen,
  • Li Liang,
  • Jingming Ye,
  • Ling Xu,
  • Meng Liu

摘要

Purpose

The intricateness of tumor immune microenvironment types (TIMTs) complicates identifying responders to immune checkpoint inhibitors (ICIs). Our purpose was to explore the metabolic characteristics of TIMTs in breast cancer using 18F-fluorodeoxyglucose (FDG) PET/CT and to establish radiomics-based predictive models for TIMTs.

Methods

Consecutive 207 breast cancer patients (211 primary lesions), who underwent 18F-FDG PET/CT examination from Sep 2022 to Aug 2024 in our hospital, were retrospectively reviewed. The programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) were evaluated for TIMTs: TMIT-I (PD-L1-, TILs-), TMIT-II (PD-L1+, TILs+), TMIT-III (PD-L1-, TILs+), and TMIT-IV (PD-L1+, TILs-). The relationship between metabolic parameters (such as maximum standardized uptake value (SUVmax) and tumor-to-liver SUV ratio (TLR)) and TIMTs was analyzed. Then composite predictive models based on radiomics were further developed.

Results

TIMT-II represented the highest proportion in HER2+ (14/22, 64%) and triple-negative (17/27, 63%) breast cancer. Most metabolic parameters (such as SUVmax and TLR) exhibited significant differences in TIMT-II vs. -I or TIMT-II vs. -III (P < 0.05). TLR (P = 0.03; OR: 1.1) and Nottingham grade (P = 0.006; OR: 3.1) were independent impact factors of TIMT-II. We further developed a composite model that integrated radiomics, metabolic parameter, and clinicopathological data, which demonstrated promising predictive efficacy for TIMT-II (AUC testing set = 0.86).

Conclusion

Metabolic differences existed among different TIMTs, with TIMT-II exhibiting markedly elevated metabolic characteristics. The composite model based on radiomics demonstrated high predictive efficacy for TIMT-II and has the potential to screen ICIs responders.